tobramycin has been researched along with Pneumonia, Bacterial in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (14.29) | 18.2507 |
| 2000's | 22 (44.90) | 29.6817 |
| 2010's | 19 (38.78) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, S; Ataei, B; Hakamifard, A; Homayouni, A; Khorvash, F; Torfeh Esfahani, AA | 1 |
| Andrinopoulou, ER; Bos, AC; Janssens, HM; Mouton, JW; Tiddens, HAWM; van Westreenen, M | 1 |
| Antony, VB; Carden, JL; Gaggar, A; Garcia, BA; Goodwin, DL; Leon, K; Rowe, SM; Smith, TA; Solomon, GM | 1 |
| Castellazzi, ML; Claut, LE; Colombo, C; Daccò, V; Esposito, S | 1 |
| Allenet, B; Bedouch, P; Camara, B; Chanoine, S; Duron, D; Epaulard, O; Lepelley, M; Peron, M | 1 |
| Brown, D; Drusano, GL; Fikes, S; Liu, W; Louie, A | 1 |
| Bargon, J; Gessler, T; Haidl, P; Pfeifer, M; Randerath, W; Voshaar, T; Wachall, B | 1 |
| Brownlee, K; Harnan, S; Mildred, M; Tappenden, P; Taylor, C; Uttley, L; Walshaw, M | 1 |
| Barraud, N; Buson, A; Jarolimek, W; Rice, SA | 1 |
| Dallow, J; Huband, MD; Krause, KM; Nichols, WW; Otterson, LG | 1 |
| Heuer, HE; Krippner, F; Merkel, N; Posselt, HG; Rietschel, E; Sieder, C; Staab, D; van Koningsbruggen-Rietschel, S; Ziegler, J | 1 |
| Brackman, G; Cappoen, D; Coenye, T; Cos, P; Crabbé, A; Rigole, P; Van den Driessche, F; Vanhoutte, B; Vercruysse, J; Verstraete, G; Vervaet, C | 1 |
| Abdulhamid, I; Andrews, S; Biglin, K; Lehr, VT; Wise, TL | 1 |
| Heijerman, HG; Kingma, H; Rijntjes, E; Scheenstra, RJ; Tavy, DL | 1 |
| Chavanet, P; Croisier, D; Martha, B; Piroth, L | 1 |
| Baker, WR; Barker, LM; Burns, JL; Gurgel, JL; Kenney, TF; MacLeod, DL; Moss, SC; Sutherland, JL | 1 |
| Ballmann, M; Claass, A; Doering, G; Franke, P; Junge, S; Riethmueller, J; Schroeter, TW; Stern, M; von Butler, R | 1 |
| Ballmann, M; Broemme, S; Claass, A; Doering, G; Franke, P; Hebestreit, A; Jeschke, R; Junge, S; Koetz, K; Kuemmerer, K; Riethmueller, J; Schroeter, TW; Staab, D; Stern, M | 1 |
| Bjarnsholt, T; Calum, H; Christensen, LD; Christophersen, L; Ciofu, O; Givskov, M; Hougen, HP; Høiby, N; Jensen, PØ; Molin, S; Moser, C; van Gennip, M | 1 |
| Abdelrahim, ME; Diot, P; Dubus, JC; Galle, J; Montharu, J; Vecellio, L | 1 |
| Bhavsar, T; Cantor, J; Liu, M; Liu, X | 1 |
| Bothra, M; Kabra, SK; Lodha, R | 1 |
| Arnold, HM; Kollef, MH; Sawyer, AM | 1 |
| Balp, MM; Kulich, K; Regnault, A; Viala-Danten, M | 1 |
| Beisty, J; Clough, D; Jones, A; Keevil, B; McKenna, D; Morris, J; Webb, K | 1 |
| Al-Khadra, ES; Barone, CP; Chau, KW; Colin, AA | 1 |
| Moore, ME; Mueller, EW | 1 |
| Alothman, GA; Alsaadi, MM; Coates, AL; Corey, M; Dupuis, A; Ho, BL; Ho, SL | 1 |
| Dickson, EW; Doern, GV; Heard, SO; Mazzoni, M; Trevino, L | 1 |
| Ariza, J; Ayats, J; Borraz, C; Cabellos, C; Corbella, X; Doménech, A; Gudiol, F; Montero, A; Tubau, F | 1 |
| de la Cal, MA; Kolak, J; Peric, M; Silvestre, L; van Saene, HK | 1 |
| Campbell, P; Marshall, BC; Mayer-Hamblett, N; Saiman, L | 1 |
| Alvarez, A; Baquero, F; Cantón, R; Cobos, N; de Gracia, J; García-Quetglas, E; Gartner, S; Honorato, J; Oliver, A; Salcedo, A | 1 |
| Chavanet, P; Croisier, D; Durand, D; Hocquet, D; Martha, B; Piroth, L; Plesiat, P; Portier, H | 1 |
| Cannella, CA; Wilkinson, ST | 1 |
| Anbar, RD; Awa, E; Santos, RP | 1 |
| Davidson, TM; Light, M; Mitchell, M; Murphy, C; Smith, C | 1 |
| Ciofu, O; Giwercman, B; Høiby, N; Pedersen, SS | 1 |
| Church, DA; Echols, RM; Haverstock, DC; Kanga, JF; Kuhn, RJ; Painter, BG; Perroncel, RY; Rubio, TT; Spohn, WA; Stevens, JC; Thurberg, BE | 1 |
| Chang, SC; Ho, SW; Hsieh, WC; Hsueh, PR; Luh, KT; Teng, LJ; Wang, SK; Yang, PC | 1 |
| Sieger, B | 1 |
| Ategbo, S; Canis, F; Husson, MO; Trivier, D; Turck, D; Vic, P | 1 |
| Baines, P; Hughes, J; Jones, A; Makura, Z; Morar, P; Selby, A; van Saene, R | 1 |
| Baron, D; Bironneau, E; Clémenti, E; Cousson, J; Le Conte, P; Legras, A; Potel, G; Villers, D | 1 |
| Bärmeier, H; Bartel, K; Böwing, B; Habash, T; Heininger, U; Lugauer, S; Schoerner, C; Unsal, M | 1 |
| Lacy, MK; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R | 1 |
| Bingen, E; Bonacorsi, S; Brahimi, N; Gérardin, M; Lebourgeois, M; Mariani-Kurkdjian, P; Munck, A; Navarro, J | 1 |
| Moss, RB | 1 |
| Hubert, D; Sermet-Gaudelus, I; Turck, D | 1 |
3 review(s) available for tobramycin and Pneumonia, Bacterial
| Article | Year |
|---|---|
Tobramycin for the treatment of bacterial pneumonia in children.
Topics: Administration, Inhalation; Anti-Infective Agents; Child; Clinical Trials, Phase III as Topic; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Tobramycin | 2012 |
Control of bacterial pneumonia during mechanical ventilation.
Topics: Amphotericin B; Anti-Bacterial Agents; Cefotaxime; Chemoprevention; Cross Infection; Equipment Contamination; Humans; Hygiene; Intensive Care Units; Length of Stay; Pneumonia, Bacterial; Polymyxin B; Respiration, Artificial; Tobramycin | 2005 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Inhalation; Injections, Intravenous; Lung Diseases; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
14 trial(s) available for tobramycin and Pneumonia, Bacterial
| Article | Year |
|---|---|
Comparing inhaled colistin with inhaled fosfomycin/tobramycin as an adjunctive treatment for ventilator-associated pneumonia: An open-label randomized controlled trial.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Fosfomycin; Humans; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Tobramycin; Treatment Outcome | 2023 |
[Effect of Inhalation of Tobramycin for 12 Months on Reduction of Hospitalisation Rate in Severe COPD].
Topics: Administration, Inhalation; Aged; Causality; Comorbidity; Double-Blind Method; Female; Germany; Hospitalization; Humans; Male; Medication Adherence; Middle Aged; Pneumonia, Bacterial; Prevalence; Pulmonary Disease, Chronic Obstructive; Respiratory System Agents; Risk Factors; Severity of Illness Index; Tobramycin; Treatment Outcome | 2013 |
Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Male; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Serum; Tobramycin; Young Adult | 2016 |
Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Infant; Infusions, Intravenous; Male; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2009 |
Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ceftazidime; Child; Child, Preschool; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2009 |
Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Male; Medication Adherence; Nebulizers and Vaporizers; Patient Satisfaction; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Psychometrics; Reproducibility of Results; Surveys and Questionnaires; Tobramycin; Young Adult | 2012 |
Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Drug Monitoring; Humans; Pneumonia, Bacterial; Tobramycin | 2012 |
Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin.
Topics: Administration, Inhalation; Adolescent; Bronchial Hyperreactivity; Bronchoconstriction; Child; Cross-Over Studies; Cystic Fibrosis; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Pneumonia, Bacterial; Preservatives, Pharmaceutical; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Spirometry; Tobramycin | 2002 |
Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Azithromycin; Cystic Fibrosis; Deoxyribonuclease I; Drug Monitoring; Forced Expiratory Volume; Genotype; Heterozygote; Homozygote; Hospitalization; Humans; Pneumonia, Bacterial; Predictive Value of Tests; Proportional Hazards Models; Pseudomonas Infections; Risk Factors; Severity of Illness Index; Tobramycin; Treatment Outcome; United States | 2005 |
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Topics: Acute Disease; Adolescent; Anti-Infective Agents; Arthralgia; Ceftazidime; Child; Child, Preschool; Ciprofloxacin; Cystic Fibrosis; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Pneumonia, Bacterial; Prospective Studies; Pseudomonas Infections; Tobramycin; Treatment Outcome | 1997 |
[Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Topics: Adolescent; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Ceftazidime; Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Humans; Pneumonia, Bacterial; Pseudomonas Infections; Tobramycin | 1998 |
[Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study].
Topics: Adult; Aerosols; Aged; Anti-Bacterial Agents; Creatinine; Cross Infection; Data Interpretation, Statistical; Double-Blind Method; Drug Tolerance; Female; Humans; Intubation, Intratracheal; Kidney; Male; Middle Aged; Placebos; Pneumonia, Bacterial; Respiration; Respiration, Artificial; Time Factors; Tobramycin; Treatment Outcome | 2000 |
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.
Topics: Adult; Aged; Ceftazidime; Cephalosporins; Critical Care; Cross Infection; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Safety; Tobramycin | 2001 |
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Cystic Fibrosis; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Long-Term Care; Male; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2002 |
32 other study(ies) available for tobramycin and Pneumonia, Bacterial
| Article | Year |
|---|---|
Patient-specific modelling of regional tobramycin concentration levels in airways of patients with cystic fibrosis: can we dose once daily?
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Computer Simulation; Cystic Fibrosis; Drug Delivery Systems; Female; Humans; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas Infections; Respiratory System; Retrospective Studies; Tobramycin | 2017 |
Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.
Topics: Administration, Inhalation; Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Azithromycin; Burkholderia cepacia complex; Burkholderia Infections; Ceftazidime; Clinical Protocols; Cohort Studies; Consolidation Chemotherapy; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies; Tobramycin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult | 2018 |
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in two young children: the importance of an early diagnosis.
Topics: Child, Preschool; Drug Hypersensitivity Syndrome; Drug Therapy, Combination; Early Diagnosis; Eosinophilia; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Osteomyelitis; Piperacillin; Pneumonia, Bacterial; Risk Assessment; Sampling Studies; Tobramycin; Vancomycin; Withholding Treatment | 2018 |
A successful antibiotic treatment by a new administration route: a case report of a subcutaneous administration of ceftazidime and tobramycin.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Humans; Injections, Subcutaneous; Male; Pneumonia, Bacterial; Tobramycin | 2019 |
Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lung; Meropenem; Mice; Microbial Sensitivity Tests; Models, Theoretical; Pneumonia, Bacterial; Pseudomonas aeruginosa; Thienamycins; Tobramycin; Treatment Outcome | 2013 |
The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Decision Support Techniques; Dry Powder Inhalers; Humans; Models, Economic; Pneumonia, Bacterial; Probability; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Tobramycin; Young Adult | 2014 |
Mannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms.
Topics: Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Diuretics, Osmotic; Drug Resistance, Bacterial; Humans; Mannitol; Mutation; Pneumonia, Bacterial; Pseudomonas aeruginosa; Tobramycin | 2013 |
Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Ceftazidime; Cross Infection; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Minocycline; Pneumonia, Bacterial; Pulmonary Surfactants; Tigecycline; Tobramycin | 2014 |
Evaluation of combination therapy for Burkholderia cenocepacia lung infection in different in vitro and in vivo models.
Topics: A549 Cells; Animals; Biofilms; Burkholderia cenocepacia; Burkholderia Infections; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Econazole; Female; Humans; Mice; Mice, Inbred BALB C; Miconazole; Pneumonia, Bacterial; Tobramycin | 2017 |
Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Fatal Outcome; Humans; Infant, Newborn; Infant, Premature; Male; Pneumonia, Bacterial; Tobramycin | 2008 |
Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.
Topics: Adult; Anti-Bacterial Agents; Caloric Tests; Cohort Studies; Cystic Fibrosis; Dizziness; Dose-Response Relationship, Drug; Electronystagmography; Female; Humans; Male; Meniere Disease; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Pseudomonas Infections; Tobramycin; Vestibular Diseases; Vestibule, Labyrinth | 2009 |
In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Colony Count, Microbial; Drug Therapy, Combination; Humans; Infusions, Intravenous; Lung; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas Infections; Rabbits; Spleen; Tobramycin | 2008 |
Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Bronchiectasis; Colony Count, Microbial; Drug Combinations; Drug Interactions; Fosfomycin; Humans; Lung; Male; Microbial Sensitivity Tests; Microbial Viability; Pneumonia, Bacterial; Rats; Tobramycin; Treatment Outcome | 2009 |
Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Chemokine CXCL2; Colony Count, Microbial; Cystic Fibrosis; Disease Models, Animal; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung; Mice; Mice, Inbred BALB C; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Severity of Illness Index; Time Factors; Tobramycin | 2009 |
Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Cystic Fibrosis; Data Collection; Equipment Reuse; Humans; Lung; Masks; Nebulizers and Vaporizers; Papio; Particle Size; Pneumonia, Bacterial; Tobramycin | 2011 |
Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Cricetinae; Disease Models, Animal; Drug Synergism; Female; Humans; Lung; Mesocricetus; Muramidase; Neutrophils; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Tobramycin | 2011 |
Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Administration, Inhalation; Aerosols; Anti-Bacterial Agents; APACHE; Bronchoalveolar Lavage; Colistin; Comorbidity; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Tobramycin; Treatment Outcome | 2012 |
Invasive pneumonia and septic shock in infants as a presentation of cystic fibrosis with vitamin-deficiency.
Topics: Ampicillin; Anti-Bacterial Agents; Avitaminosis; Ceftazidime; Cystic Fibrosis; Drug Therapy, Combination; Humans; Infant; Male; Pneumonia, Bacterial; Respiration, Artificial; Respiratory Insufficiency; Shock, Septic; Tobramycin; Treatment Outcome | 2012 |
Aerosolized antibiotic therapy: a forward aerial assault or forced contingency for ventilator-associated pneumonia?
Topics: Acinetobacter Infections; Anti-Bacterial Agents; Colistin; Female; Humans; Male; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Pseudomonas Infections; Tobramycin | 2012 |
Prevention of descending pneumonia in rts with perflubron-delivered tobramycin.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Disease Models, Animal; Intubation; Klebsiella Infections; Klebsiella pneumoniae; Pneumonia, Bacterial; Prospective Studies; Rats; Rats, Wistar; Tobramycin; Ventilators, Mechanical | 2003 |
Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Colistin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Pneumonia, Bacterial; Rifampin; Tobramycin | 2004 |
In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Proteins; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tobramycin | 2006 |
Acute renal failure associated with inhaled tobramycin.
Topics: Acute Kidney Injury; Administration, Inhalation; Anti-Bacterial Agents; Female; Humans; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2006 |
Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.
Topics: Administration, Inhalation; Bronchial Spasm; Child, Preschool; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Pneumonia, Bacterial; Prednisone; Pulmonary Eosinophilia; Recurrence; Risk Assessment; Severity of Illness Index; Tobramycin | 2007 |
Management of chronic sinusitis in cystic fibrosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Clinical Protocols; Combined Modality Therapy; Cystic Fibrosis; Endoscopy; Humans; Lung Transplantation; Maxillary Sinus; Nasal Polyps; Nasal Septum; Pneumonia, Bacterial; Preoperative Care; Pseudomonas Infections; Respiratory Tract Infections; Rhinitis; Sinusitis; Sodium Chloride; Therapeutic Irrigation; Tobramycin; Turbinates | 1995 |
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbenicillin; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Denmark; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1994 |
Bacteremia caused by Arcobacter cryaerophilus 1B.
Topics: Aged; Bacteremia; Ceftizoxime; Drug Therapy, Combination; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Pneumonia, Bacterial; Tobramycin; Uremia | 1997 |
Meropenem monotherapy as empiric treatment of nosocomial lower respiratory tract infection.
Topics: Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Critical Illness; Cross Infection; Drug Therapy, Combination; Humans; Meropenem; Pneumonia, Bacterial; Severity of Illness Index; Thienamycins; Tobramycin; Treatment Outcome | 1998 |
Topical antibiotics on tracheostoma prevents exogenous colonization and infection of lower airways in children.
Topics: Administration, Topical; Adolescent; Antibiotic Prophylaxis; Bacteriological Techniques; Child; Child, Preschool; Cohort Studies; Colistin; Cross Infection; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Male; Oropharynx; Pilot Projects; Pneumonia, Bacterial; Prospective Studies; Tobramycin; Tracheostomy; Treatment Outcome | 2000 |
Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.
Topics: Adult; Anti-Bacterial Agents; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Humans; Male; Pneumonia, Bacterial; Predictive Value of Tests; Pseudomonas Infections; Retrospective Studies; Secondary Prevention; Tobramycin; Treatment Outcome | 1999 |
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.
Topics: Administration, Inhalation; Administration, Oral; Ceftazidime; Child; Child, Preschool; Chronic Disease; Colistin; Colony Count, Microbial; Cystic Fibrosis; DNA, Bacterial; Drug Therapy, Combination; Electrophoresis, Gel, Pulsed-Field; Female; Genotype; Humans; Imipenem; Infant; Male; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Tobramycin | 2001 |
[Inhalational antibiotic therapy in mucoviscidosis. Apropos of a galenic form of tobramycin].
Topics: Administration, Inhalation; Bronchitis; Child; Child, Preschool; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Infant; Infant, Newborn; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2001 |